BioProduct : Chemicals & Compounds : Axitinib
Previous  Next
Visit the product
Product Name Axitinib
Product PageVisit the Product
Product Description Axitinib is currently in phase I to III development in a range of solid tumors. In nonclinical and clinical studies, the compound has been shown to inhibit angiogenesis, vascular permeability, and blood flow . In phase II studies, axitinib showed single-agent activity in a wide range of tumor types, including advanced renal cell carcinoma and melanoma as well as improved progression-free survival and overall survival in advanced and metastatic pancreatic cancer when combined with gemcitabine. In transfected or endogenous RTK-expressing cells, axitinib potently blocked growth factor-stimulated phosphorylation of VEGFR-2 and VEGFR-3 with average IC50 values of 0.2 and 0.1 to 0.3 nmol/L, respectively. Cellular activity against VEGFR-1 was 1.2 nmol/L (measured in the presence of 2.3% bovine serum albumin), equivalent to an absolute IC50 of -0.1 nmol/L, based on protein binding of axitinib. The potency against murine VEGFR-2 (Flk-1) in Flk-1-transfected NIH-3T3 cells was 0.18 nmol/L, similar to that of its human homologue.
Product Manual Read Product Manual
Price $95
Product Review 0
Vendor Information Selleck
2626 South Loop West, Suite 225, Houston, TX 77054 USA